Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.99
ILMN's Cash to Debt is ranked higher than
68% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. ILMN: 0.99 )
ILMN' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: 0.99

Equity to Asset 0.39
ILMN's Equity to Asset is ranked higher than
55% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ILMN: 0.39 )
ILMN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.94
Current: 0.39

0.36
0.94
Interest Coverage 3.38
ILMN's Interest Coverage is ranked lower than
51% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. ILMN: 3.38 )
ILMN' s 10-Year Interest Coverage Range
Min: 3.38   Max: 9999.99
Current: 3.38

3.38
9999.99
F-Score: 6
Z-Score: 9.21
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.21
ILMN's Operating margin (%) is ranked higher than
93% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. ILMN: 22.21 )
ILMN' s 10-Year Operating margin (%) Range
Min: -1775.02   Max: 23.45
Current: 22.21

-1775.02
23.45
Net-margin (%) 16.17
ILMN's Net-margin (%) is ranked higher than
92% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. ILMN: 16.17 )
ILMN' s 10-Year Net-margin (%) Range
Min: -1421.39   Max: 21.65
Current: 16.17

-1421.39
21.65
ROE (%) 20.53
ILMN's ROE (%) is ranked higher than
93% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. ILMN: 20.53 )
ILMN' s 10-Year ROE (%) Range
Min: -84.48   Max: 24.99
Current: 20.53

-84.48
24.99
ROA (%) 9.23
ILMN's ROA (%) is ranked higher than
88% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. ILMN: 9.23 )
ILMN' s 10-Year ROA (%) Range
Min: -43.21   Max: 19.92
Current: 9.23

-43.21
19.92
ROC (Joel Greenblatt) (%) 104.32
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. ILMN: 104.32 )
ILMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -537.44   Max: 96.63
Current: 104.32

-537.44
96.63
Revenue Growth (%) 17.30
ILMN's Revenue Growth (%) is ranked higher than
91% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ILMN: 17.30 )
ILMN' s 10-Year Revenue Growth (%) Range
Min: -2   Max: 160.9
Current: 17.3

-2
160.9
EBITDA Growth (%) 6.40
ILMN's EBITDA Growth (%) is ranked higher than
76% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. ILMN: 6.40 )
ILMN' s 10-Year EBITDA Growth (%) Range
Min: -70.3   Max: 529.1
Current: 6.4

-70.3
529.1
EPS Growth (%) 1.10
ILMN's EPS Growth (%) is ranked higher than
70% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ILMN: 1.10 )
ILMN' s 10-Year EPS Growth (%) Range
Min: -40.2   Max: 205.7
Current: 1.1

-40.2
205.7
» ILMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ILMN Guru Trades in Q4 2013

Andreas Halvorsen 1,696,962 sh (New)
PRIMECAP Management 2,048,063 sh (+0.61%)
Paul Tudor Jones 3,100 sh (unchged)
George Soros 10,102 sh (unchged)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Stanley Druckenmiller 506,700 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Steven Cohen Sold Out
Ron Baron 2,209,790 sh (-0.3%)
Mario Gabelli 16,500 sh (-10.81%)
Pioneer Investments 61,619 sh (-28.46%)
Jim Simons 44,618 sh (-72.91%)
» More
Q1 2014

ILMN Guru Trades in Q1 2014

RS Investment Management 9,315 sh (New)
Steven Cohen 76,780 sh (New)
Jim Simons 365,118 sh (+718.32%)
Andreas Halvorsen 8,866,245 sh (+422.48%)
George Soros 50,102 sh (+395.96%)
PRIMECAP Management 2,262,270 sh (+10.46%)
Paul Tudor Jones 3,188 sh (+2.84%)
Jean-Marie Eveillard 400 sh (unchged)
Vanguard Health Care Fund 2,160,500 sh (-3.56%)
Ron Baron 1,705,740 sh (-22.81%)
Mario Gabelli 10,400 sh (-36.97%)
Stanley Druckenmiller 253,300 sh (-50.01%)
Pioneer Investments 30,351 sh (-50.74%)
» More
Q2 2014

ILMN Guru Trades in Q2 2014

George Soros 195,102 sh (+289.41%)
Stanley Druckenmiller 410,100 sh (+61.9%)
RS Investment Management 10,350 sh (+11.11%)
Jean-Marie Eveillard 400 sh (unchged)
Vanguard Health Care Fund 2,160,500 sh (unchged)
Steven Cohen 900 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
PRIMECAP Management 2,252,780 sh (-0.42%)
Ron Baron 1,641,210 sh (-3.78%)
Andreas Halvorsen 7,992,844 sh (-9.85%)
Paul Tudor Jones 2,868 sh (-10.04%)
Mario Gabelli 6,900 sh (-33.65%)
» More
Q3 2014

ILMN Guru Trades in Q3 2014

Jim Simons 225,918 sh (New)
Joel Greenblatt 12,977 sh (New)
Steven Cohen 27,700 sh (+2977.78%)
Paul Tudor Jones 9,768 sh (+240.59%)
RS Investment Management 15,200 sh (+46.86%)
Andreas Halvorsen 8,650,670 sh (+8.23%)
Jean-Marie Eveillard 400 sh (unchged)
Stanley Druckenmiller 410,100 sh (unchged)
PRIMECAP Management 2,244,837 sh (-0.35%)
Ron Baron 1,487,075 sh (-9.39%)
Vanguard Health Care Fund 1,932,800 sh (-10.54%)
Mario Gabelli 4,100 sh (-40.58%)
George Soros 75,102 sh (-61.51%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-09-30 Add 8.23%0.43%$159.18 - $182.86 $ 181.216%8650670
George Soros 2014-09-30 Reduce -61.51%0.16%$159.18 - $182.86 $ 181.216%75102
Vanguard Health Care Fund 2014-09-30 Reduce -10.54%0.11%$159.18 - $182.86 $ 181.216%1932800
Ron Baron 2014-09-30 Reduce -9.39%0.11%$159.18 - $182.86 $ 181.216%1487075
Joel Greenblatt 2014-09-30 New Buy0.02%$159.18 - $182.86 $ 181.216%12977
Mario Gabelli 2014-09-30 Reduce -40.58%$159.18 - $182.86 $ 181.216%4100
Andreas Halvorsen 2014-06-30 Reduce -9.85%0.54%$131.05 - $177.4 $ 181.2118%7992844
George Soros 2014-06-30 Add 289.41%0.19%$131.05 - $177.4 $ 181.2118%195102
Mario Gabelli 2014-06-30 Reduce -33.65%$131.05 - $177.4 $ 181.2118%6900
Andreas Halvorsen 2014-03-31 Add 422.48%4.45%$108.61 - $179.54 $ 181.2121%8866245
Ron Baron 2014-03-31 Reduce -22.81%0.23%$108.61 - $179.54 $ 181.2121%1705740
George Soros 2014-03-31 Add 395.96%0.06%$108.61 - $179.54 $ 181.2121%50102
Mario Gabelli 2014-03-31 Reduce -36.97%$108.61 - $179.54 $ 181.2121%10400
Andreas Halvorsen 2013-12-31 New Buy0.88%$75.58 - $110.38 $ 181.2193%1696962
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Illumina Inc

Baron Funds Comments on Illumina Inc. - May 29, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 21, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)





From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 12, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)



From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 02, 2014

Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the quarter, driven by better-than-expected fourth quarter results, strong 2014 financial guidance, and the announcement of multiple new product introductions. The company's most exciting new product is an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe these developments support our view that Illumina has meaningfully distanced itself from its competitors. We believe that nearly all new orders in the sequencing industry are being won by Illumina, affording the company a de facto monopoly in DNA sequencing devices. Further, Illumina retains this remarkable competitive position at a time when demand for next generation DNA sequencing is accelerating rapidly.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 08, 2013

Shares of Illumina, Inc. (ILMN) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman)

From Ron Baron’s second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 02, 2013

Illumina, Inc. (ILMN) is the leading manufacturer of instruments and consumables used by scientists engaged in researching applications for 'next generation' DNA sequencing. Illumina's products have been at the forefront of huge recent advances in technology that have brought the cost of sequencing a human genome from roughly $1 billion 23 years ago, when the Human Genome Project was launched, to $3,000 today (and still declining rapidly). The company reported quarterly revenue and earnings growth ahead of Wall Street estimates, driven by strength across its entire product portfolio.We believe these results were driven by both growing end markets and market share gains, which may have accelerated after the company's main competitor announced it was considering selling itself.

From the Baron Funds’ second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 01, 2013

Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis.

From Baron Funds’ first quarter 2013 letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the quarter, driven by better-than-expected fourth quarter results, strong 2014 financial guidance, and the announcement of multiple new product introductions. The company's most exciting new product is an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe these developments support our view that Illumina has meaningfully distanced itself from its competitors. We believe that nearly all new orders in the sequencing industry are being won by Illumina, affording the company a de facto monopoly in DNA sequencing devices. Further, Illumina retains this remarkable competitive position at a time when demand for next generation DNA sequencing is accelerating rapidly. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 95.30
ILMN's P/E(ttm) is ranked higher than
69% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.00 vs. ILMN: 95.30 )
ILMN' s 10-Year P/E(ttm) Range
Min: 34.32   Max: 344.72
Current: 95.3

34.32
344.72
P/B 20.20
ILMN's P/B is ranked higher than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. ILMN: 20.20 )
ILMN' s 10-Year P/B Range
Min: 2.33   Max: 23.59
Current: 20.2

2.33
23.59
P/S 15.42
ILMN's P/S is ranked lower than
51% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. ILMN: 15.42 )
ILMN' s 10-Year P/S Range
Min: 3.4   Max: 16.77
Current: 15.42

3.4
16.77
PFCF 71.34
ILMN's PFCF is ranked higher than
74% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 57.37 vs. ILMN: 71.34 )
ILMN' s 10-Year PFCF Range
Min: 13.32   Max: 138.5
Current: 71.34

13.32
138.5
EV-to-EBIT 66.50
ILMN's EV-to-EBIT is ranked higher than
67% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. ILMN: 66.50 )
ILMN' s 10-Year EV-to-EBIT Range
Min: -97.5   Max: 415.7
Current: 66.5

-97.5
415.7
PEG 6.28
ILMN's PEG is ranked higher than
84% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ILMN: 6.28 )
ILMN' s 10-Year PEG Range
Min: 1.21   Max: 15.23
Current: 6.28

1.21
15.23
Shiller P/E 191.46
ILMN's Shiller P/E is ranked higher than
75% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 139.22 vs. ILMN: 191.46 )
ILMN' s 10-Year Shiller P/E Range
Min: 87.03   Max: 2630.5
Current: 191.46

87.03
2630.5
Current Ratio 2.23
ILMN's Current Ratio is ranked higher than
64% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. ILMN: 2.23 )
ILMN' s 10-Year Current Ratio Range
Min: 0.99   Max: 60.21
Current: 2.23

0.99
60.21
Quick Ratio 1.99
ILMN's Quick Ratio is ranked higher than
73% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. ILMN: 1.99 )
ILMN' s 10-Year Quick Ratio Range
Min: 0.87   Max: 60.21
Current: 1.99

0.87
60.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 102.96
ILMN's Price/Tangible Book is ranked higher than
55% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.44 vs. ILMN: 102.96 )
ILMN' s 10-Year Price/Tangible Book Range
Min: 1.18   Max: 457.79
Current: 102.96

1.18
457.79
Price/DCF (Projected) 5.84
ILMN's Price/DCF (Projected) is ranked higher than
72% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.64 vs. ILMN: 5.84 )
ILMN' s 10-Year Price/DCF (Projected) Range
Min: 1.53   Max: 72.48
Current: 5.84

1.53
72.48
Price/Median PS Value 1.92
ILMN's Price/Median PS Value is ranked higher than
55% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. ILMN: 1.92 )
ILMN' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 94.53
Current: 1.92

0.5
94.53
Price/Peter Lynch Fair Value 5.37
ILMN's Price/Peter Lynch Fair Value is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ILMN: 5.37 )
ILMN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.73   Max: 9.68
Current: 5.37

1.73
9.68
Price/Graham Number 20.47
ILMN's Price/Graham Number is ranked higher than
70% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ILMN: 20.47 )
ILMN' s 10-Year Price/Graham Number Range
Min: 3.3   Max: 48.38
Current: 20.47

3.3
48.38
Earnings Yield (Greenblatt) 1.50
ILMN's Earnings Yield (Greenblatt) is ranked higher than
65% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. ILMN: 1.50 )
ILMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 7.2
Current: 1.5

0.2
7.2
Forward Rate of Return (Yacktman) 18.83
ILMN's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.33 vs. ILMN: 18.83 )
ILMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.3   Max: 38.1
Current: 18.83

-9.3
38.1

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:ILU.Germany, ILMN.Mexico,
Illumina, Inc. was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company is a developer, manufacturer and marketer of integrated systems for the analysis of genetic variation and biological function. Using its proprietary technologies, it provides a line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and it expects to enter the market for molecular diagnostics. The Company's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. The Company's product and service offerings also include leading-edge solutions for single-nucleotide polymorphism genotyping, copy number variation, DNA methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein.The Company's Life Sciences Business Unit includes all products and services that are mainly related to the research market, namely the product lines based on its sequencing, BeadArray, and real-time PCR technologies.The Diagnostics operating segment focused on opportunities in molecular diagnostics. The Company's manufacturing operations require a variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. The Company's competitors are Affymetrix, Inc.; Agilent Technologies, Inc.; BGI; Luminex Corporation; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Roche Holding AG.; and Thermo Fisher Scientific, Inc., among others. The Company's trademarks includes Illumina, illuminaDx, BaseSpace, BeadArray, BeadXpress, BlueGnome, cBot, CSPro, DASL, DesignStudio, Epicentre, GAIIx, Genetic Energy, Genome Analyzer, GenomeStudio, GoldenGate, HiScan, HiSeq, HiSeq X, Infinium, iSelect, MiSeq, MiSeqDx, NeoPrep, NextBio, Nextera, NextSeq, SeqMonitor, Solexa, TruGenome, TruSeq, TruSight, Understand Your Genome, UYG, VeraCode, the pumpkin orange color, and the Genetic Energy streaming bases design are certain of its trademarks. The Company's operations require the use of hazardous materials that subject the Company to a variety of federal, state, and local environmental and safety laws and regulations.
» More Articles for ILMN

Headlines

Articles On GuruFocus.com
HTG Announces Completion of IVD Development and Supply Agreement With Illumina Oct 30 2014 
Top Insider Sells Highlight: Illumina Inc. Jul 25 2014 
Weekly CFO Sells Highlight: Envision Healthcare Holdings Inc, Google Inc, Illumina Inc. Jul 20 2014 
Baron Funds Comments on Illumina Inc. May 29 2014 
Baron Funds Comments on Illumina Inc. May 21 2014 
Baron Funds Comments on Illumina Inc. May 12 2014 
Baron Funds Comments on Illumina Inc. May 02 2014 
Weekly 52-Week Highs Highlight: SHPG, ILMN, UA, WDAY Feb 23 2014 
Illumina Inc: How Long Can a Miracle Go On? Feb 07 2014 
Baron Funds Comments on Illumina Inc. Aug 08 2013 


More From Other Websites
Stocks Hold Near Highs Ahead of Fed Announcement Dec 17 2014
Stocks Stage Comeback; Leaders Still Under Pressure Dec 15 2014
Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4% Dec 10 2014
Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session Dec 10 2014
uniQure N.V. (QURE) Jumps: Stock Adds 6.3% in Session Dec 08 2014
My 2014 Healthcare Top 10 List Dec 06 2014
ILLUMINA INC Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 05 2014
Tesla hits oil slick Dec 03 2014
Sequenom (SQNM) Stock Spikes Following NIPT Patent Settlement With Illumina Dec 03 2014
Sequenom climbs as Illumina patent dispute ends Dec 03 2014
Sequenom climbs as Illumina patent dispute ends Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
UK wage conundrum in spotlight ahead of Autumn Statement Dec 03 2014
Alexandria Real Estate REIT Inks Rx For Pharma Boom Dec 02 2014
Intra-Cellular Therapies (ITCI) Jumps: Stock Rises 6.8% Dec 02 2014
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% Nov 28 2014
'Why nearly every share is in danger' Nov 24 2014
Is Illumina (ILMN) Worth Adding to Your Portfolio? Nov 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK